Bertrand Jordan,
Emeritus Research Director,
National Centre for Scientific Research
Bertrand R Jordan (CNRS emeritus research director), an academic molecular biologist with particular achievements in the field of molecular immunology, is the founder and coordinator of the Marseille-Nice Genopole genomics consortium and counselor to the CoreBio-PACA technical platform organisation. An early contributor to DNA array development since 1995, he is also a consultant for French (Ipsogen), Dutch (PamGene) and Taiwanese (Phalanx, Dr. Chip) microarray companies, that operate in fields ranging from prognostic and predictive expression profiling in breast cancer, to “companion diagnostics” based on multiplex kinase activity measurement, and to efficient bacterial diagnostics in the food industry. He recently coordinated a book, “Microarrays in diagnostics and biomarker development” (Springer, 2012).
Requirements for Clinical Utility of Expression Signatures and SNP Profiles based on Microarray Data
Thursday, 18 September 2014 at 20:50
Add to Calendar ▼2014-09-18 20:50:002014-09-18 21:50:00Europe/LondonRequirements for Clinical Utility of Expression Signatures and SNP Profiles based on Microarray DataLab-on-a-Chip, Microfluidics and Microarray World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
DNA microarrays have allowed extensive expression profiling of normal and pathological samples as well as whole-genome association studies aimed at finding the genes involved in frequent, multigenic diseases. While this has provided much new knowledge, the transition to actual clinical applications has been limited. Expression profiles have been applied for prognostic and predictive purposes, particularly in oncology and for breast cancer. Many tests (>50) have been proposed and published, but only a few are actually used and only one or two can be considered commercially successful. This is due to the need for a very robust implementation, to the required demonstration of analytical validity, clinical validity and above all clinical utility, in addition to regulatory requirements and cost/reimbursement issues. Whole-genome SNP profiling has revolutionised the genetics of complex diseases, with the successful implementation of GWAS studies that have at last provided solid identification of loci and genes influencing common, multigenic diseases. However the relative risks associated with the deleterious alleles identified are generally small, of the order of 1.2 to 1.5, and their predictive value at the level of an individual is accordingly very limited. Profiles marketed direct to consumers have met with regulatory problems. As additional knowledge accumulates in the future, these analyses will acquire more definite medical value.
Add to Calendar ▼2014-09-18 00:00:002014-09-19 00:00:00Europe/LondonLab-on-a-Chip, Microfluidics and Microarray World CongressLab-on-a-Chip, Microfluidics and Microarray World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2014-09-18 20:50:002014-09-18 21:50:00Europe/LondonRequirements for Clinical Utility of Expression Signatures and SNP Profiles based on Microarray DataLab-on-a-Chip, Microfluidics and Microarray World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
